Welcome
to
Mental Health America of
Eastern Missouri
1905 S. Grand ● St.
Louis, MO 63104 ● 314-773-1399 ●
info@mhaem.org
|
|
Welcome
to
|
|
|
|
||
|
Research Studies and Clinical Trials in the St. Louis Area Click on the study you are interested in learning more about:
Adult Depression Study Adults with Major Depressive Disorder (Return to Index at the Top of the Page)Description: Researchers are studying the efficacy, safety and tolerability of an antidepressant medication in treatment of adults 18-65 with major depressive disorder who currently are not taking psychiatric medication. The total duration of the study is 10 weeks. This is an outpatient study. Contact: Schizophrenia Research (Return to Index at the Top of the Page) The Conte Center, Washington University School of Medicine, is conducting a study of schizophrenia. Principal Investigator: Deanna Barch, MD Sponsor: National Institute of Mental Health The major goal of the Conte Center is to improve understanding of the underlying causes and mechanisms of schizophrenia, especially during its earliest phases. Volunteers of many kinds are needed to help the Conte Center achieve its goals. If you have schizophrenia or are the brother or sister of someone with schizophrenia, you may be able to participate in research studies at Washington University School of Medicine. Participation will involve a no-cost MRI (Magnetic Resonance Imaging) scan, plus 8-10 hours for interviews and cognitive testing. Every participant in the study will receive compensation for his/her time. For further information, please call Juanita Bishop at 314-877-0756. Schizophrenia -2 (Return to Index at the Top of the Page) St. Charles Psychiatric Associates and Midwest Research Group are currently looking for patients who have been diagnosed with schizophrenia and are interested in participating in an in-patient hospitalization trial followed by an outpatient extension study. Participants must meet the following criteria:
Eligible patients will receive the following:
For more information and to see if you qualify please contact a study coordinator at 636-946-8032. Genetics and Environment in Schizophrenia (Return to Index at the Top of the Page) Washington University School of Medicine in St. Louis has been awarded a federal grant from the National Institute of Mental Health (NIMH) to identify the genetic and environmental factors that may increase or decrease a person’s susceptibility of developing schizophrenia. This study is a collaborative effort with eight other research programs in the United States and Australia. The goals of this research project are to improve our understanding of the causes of schizophrenia as well as the identification of the gene(s) that may lead to such a disorder. Project results may lead to the development of methods of prevention and forms of new treatments aimed at curing the disease. Eligibility of Participants: ¨ A participant must have schizophrenia or schizoaffective disorder. ¨ With the participant’s consent, his or her parents may be asked to participate. ¨ Each participant may be asked to complete two interviews; a confidential personal interview and family interview (approximately 2-4 hours to complete). For each interview, the participant will be paid $25.00 for a total of $50.00 ¨ Each participant may be asked to give a small blood sample for which an additional $25.00 will be paid. ¨ ALL information obtained from participants and their family members will be kept completely confidential. Benefits of Participating: ¨ The participant will be contributing to the development of better treatments for schizophrenia. ¨ The participant will be contributing to the identification of gene(s) that may increase or decrease the susceptibility to schizophrenia. For more information, please call: Juanita Bishop 314- 877-0756 Sarah Buday 314-286-1352 Jessica Wold 314-286-1420 Toll Free 1-888-925-7252 Schizophrenia and Depakote (Return to Index at the Top of the Page) Individuals with a diagnosis of schizophrenia and no history of diabetes are being invited to participate in a study on the changes in blood sugar levels and weight that might occur during treatment with Depakote and antipsychotic medications. PARTICIPATION INVOLVES: 1) A screening visit at
Barnes-Jewish Hospital (formerly Barnes Hospital). 2) Glucose
tolerance tests (three) at Barnes-Jewish Hospital. 3) Overnight
visits (two) at Barnes-Jewish Hospital. 4) Willingness to try
Depakote under the supervision of your doctor. 5) Regular check-ups
with the research team. Schizophrenia or Schizoaffective Disorder and Abilify (Return to Index at the Top of the Page) Individuals with a diagnosis of schizophrenia
or schizoaffective disorder and no history of diabetes are being
invited to participate in a study on the changes in blood sugar levels and
weight that might occur during treatment with antipsychotic medications.
PARTICIPATION INVOLVES: 1) A screening visit at Barnes-Jewish Hospital
(formerly Barnes Hospital). 2) Study related tests (glucose tolerance
tests, routine blood tests, MRI, and DXA scans) at Barnes-Jewish Hospital.
3) Willingness to try a different antipsychotic medication (Abilify)
under the supervision of your doctor.4) Regular check-ups with the
research team. Schizophrenia or
Schizoaffective Disorder and Alternate
(Return to Index at
the Top of the Page) Schizophrenia in Teenagers (13-17) (Return to Index at the Top of the Page) Could your teen have schizophrenia? Schizophrenia is a brain disorder that affects one's ability to think clearly, manage emotions, make decisions, and relate to others. Symptoms may include:
Your teen may be eligible to participate in a research study if he or she is between 13 and 17 and is experiencing the above symptoms. For more information, call: 314-205-0007 ext. 120. Inpatient Study for the Acute Exacerbation of Schizophrenia (Return to Index at the Top of the Page) The purpose of this study is to evaluate the safety, efficacy, and tolerability of an investigational medication relative to placebo in patients with acute exacerbation of schizophrenia. The duration of the study is up to 56 days, which includes a safety follow-up period after the 6 weeks of double-blind treatment. Inclusion Criteria: -Adults 18-60 years of age -Diagnosis of Schizophrenia -Within 12 months of starting the study, one psychotic episode which required hospitalization or change in medication -Body mass index between 18 and 35 *Contact for other eligibility criteria Exclusion Criteria: -Any major medical illness, psychiatric disorder, or unstable medical condition that may interfere with the study. -Active suicidal or homicidal intent or prior suicide or homicide attempt in the past 2 years -History of cataracts *Contact for other restrictions Contact: Vascular Dementia (Return to Index at the Top of the Page) Volunteers are needed to participate in a research study of an investigational drug that may manage the symptoms of vascular dementia. If someone close to you has suffered a stroke and has subsequent memory problems, he or she may be able to participate. Study volunteers must be:
Participants will receive at no charge:
Patients who complete the study will be eligible to receive open label treatment with the new drug for up to one year. For more information, call: 314-268-5880. This study is being conducted by the Clinical Trials Unit , Department of Psychiatry, Saint Louis University School of Medicine. Alzheimer's Disease Study (Over 50 Years Old) (Return to Index at the Top of the Page) Do you or someone you know have moderate to severe Alzheimer's Disease? If so, you or the person you know may be eligible to participate in a clinical research trial that could play an important role in providing a more effective treatment option in the treatment of Alzheimer's Disease. The clinical trial is now testing the safety and efficacy of an investigational drug called neramexane. This trial will investigate whether neramexane can help improve patients' abilities to understand and retain information and perform daily tasks. Participants must . . .
Potential study participants should call: 314-268-5880 or 1-800-268-5880. This study is being conducted by the Geriatric Psychiatry Division, Saint Louis University School of Medicine. Alzheimer's Disease (Over 40 Years Old) (Return to Index at the Top of the Page) Have you or someone you know been diagnosed with Alzheimer's Disease? You may be qualified to participate in a research study of an investigational medicine if you are 40 to 85 years old, and are experiencing any of these symptoms:
Qualified participants will receive study-related medical evaluations and investigational medicine at no cost. For more information, please call: 314-268-5385. This study is being conducted by the Geriatric Psychiatry Division, Saint Louis University School of Medicine. Investigational Study for Adults with Mild to Moderate Alzheimer’s Disease (Return to Index at the Top of the Page) Purpose: This is a Phase I, placebo-controlled study that consists of a single ascending-dose stage followed by a multidose, parallel-treatment stage. This study will be conducted in approximately 50 adult patients between 50-85 years old who have mild to moderate Alzheimer’s disease. Eligibility Criteria Inclusion Criteria: · Diagnosis of probable Alzheimer’s disease · Approved Alzheimer’s disease treatments must be stable for ≥ 3 months prior to screening · Other prescription medications must be stable for ≥ 1 month prior to screening Exclusion Criteria: · Female patients with reproductive potential · History of presence of any clinically significant CNS disease · History of seizures, with the exception of childhood febrile seizures Contact: The Connection Study: Oral Dimebon in Adults with Mild to Moderate Alzheimer’s Disease (Return to Index at the Top of the Page) What is the Connection Study? The Connection Study is a late-stage study of 525 patients to test the effects of Dimebon (a unique oral medication) in patients with Alzheimer’s disease. The goal of the Connection Study is to determine if Dimebon safely improves cognition (thinking and awareness), memory, daily functioning, behavior, and the ability to care for oneself. The Connection Study will also look at how Dimebon affects the lives of people caring for patients who are taking the medicine. Continuing treatment on Dimebon All patients who complete the 6-month research study will be able to receive Dimebon at no financial cost until the drug is approved. Inclusion Criteria: -Adults ≥50 years of age -Diagnosis of probable Alzheimer’s Disease -MRI or CT (brain imaging) within 3 months of enrollment -Have a reliable caregiver *Contact for other eligibility criteria Exclusion Criteria: -Any major medical illness, psychiatric disorder, or unstable medical condition within 6 months of screening that may interfere with the study. -History of clinically apparent stroke -Other neurodegenerative diseases (Parkinson’s, Huntington’s, ALS, etc.) *Contact for other restrictions
Contact: Adult Depression Study (Return to Index at the Top of the Page) If you are one of the 15 million adults affected by depression, you may be eligible to participate in a research trial of a new depression medication now being studied. You may be eligible for the study if:
All qualified participants will receive study-related care and study medication for up to 8 weeks at no cost. To find out if you qualify for this study, or for more information, please call Kim Hansen or Nan Roberts. ADVENT RESEARCH INSTITUTE (636) 916-1900 Adult Depression Study -2 (Return to Index at the Top of the Page) St. Charles Psychiatric Associates and Midwest Research Group are currently looking for patients who are struggling with depression. Criteria for study qualification:
Eligible patients will receive the following:
If you are currently suffering from symptoms of depression and are interested in trying a new medication to treat your depression, please contact a study coordinator at (636) 946-8032 or visit www.MidwestResearchGroup.com. Adults with Major Depressive Disorder (Return to Index at the Top of the Page)Description: Researchers are studying the efficacy, safety and tolerability of an antidepressant medication in treatment of adults 18-65 with major depressive disorder who currently are not taking psychiatric medication. The total duration of the study is 10 weeks. This is an outpatient study. Contact: Adult Recurrent Depression (Return to Index at the Top of the Page) St. Charles Psychiatric Associates and Midwest Research Group are currently looking for patients who are struggling with recurrent depression. Recurrent Major Depressive Disorder involves episodes of depression followed by periods of “wellness.” Criteria for study qualification:
Eligible patients will receive the following:
If you are currently suffering from symptoms of depression and are interested in trying a new medication to treat your depression, please contact a study coordinator at (636) 946-8032 or visit www.MidwestResearchGroup.com. Depression and Diabetes (Return to Index at the Top of the Page) Diabetes Can Be Depressing. Do you have diabetes and also struggle with mood swings? This could be a sign of clinical depression and it may be related to your diabetes. People with diabetes are twice as likely to have clinical depression as non-diabetics. Added to this fact, is new research that suggests depression can actually make diabetes worse. This is because the effects of depression contribute to poor blood sugar control and increase the chance of diabetic complications. To break this cycle, Washington University researchers are using Wellbutrin XL®, an FDA approved anti-depressant to relieve the depression. Unlike most anti-depressants, this study medication causes no sexual side effects or weight gain. If you or someone you care about have diabetes and suspect you might have depression (feeling sad, tired, hopeless or anxious, having trouble sleeping), you can volunteer to participate in this study. Volunteers selected will receive a free evaluation and treatment for depression for up to six months. (Please note: not all people with depression respond to Wellbutrin XL.) If you have diabetes and depression symptoms, here is a chance to improve your mood. For more information or to enroll in the study, contact Emily at 314-362-5404. Principal Investigator: Dr. Patrick Lustman. Depression in the Elderly (1) (Return to Index at the Top of the Page) Conducted by Mercy Medical Group. If you are age 65 or older and have:
You may be suffering from depression, and you may be eligible to participate in a research study of an investigational medication. Participation includes:
For more information, call: 314-205-0007 ext 120 or 1-877-883-5056. Depression in the Elderly (2) (Return to Index at the Top of the Page) Conducted by Saint Louis University School of Medicine, Division of Geriatric Psychiatry. SLU School of Medicine is screening male and female volunteers aged 65 and older to participate in a research study for the treatment of major depressive disorder (MDD). Partipation in this study involves 9 visits over a period of 13 weeks. Qualified participants will receive study-related exams, lab tests, electrocardiogram, and investigational study medicine at no charge. Symptoms of major depression include:
For an initial screening, call Christina Morefield, RN, MEd at 314-268-5385. Depression in Families (Return to Index at the Top of the Page) Washington University School of Medicine is studying the genetic and environmental factors associated with Recurrent Major Depression. Dr. John Rice is the Principal Investigator. We are seeking families with two or more brothers and/or sisters who . . .
Volunteers will take part in one home or office visit of approximately 2-4 hours, with a personal and family interview. There will also be a small blood draw for the genetic analysis phase of the project. For more information, please call: 314-286-1345 or (toll-free) 1-888-292-1210. Study website: http://zork.wustl.edu/depression Child and Adolescent Depression (Return to Index at the Top of the Page) Is your child, age 7 - 17, experiencing the following symptoms?
Mercy Health Research is seeking volunteers to participate in a child and adolescent depression research study. Participation includes:
For more information, call: 314-205-0007 ext 120 or 1-877-883-5056. Bipolar Disorder -2 (Return to Index at the Top of the Page) St. Charles Psychiatric Associates and Midwest Research Group are currently looking for patients who have been diagnosed with Bipolar I Disorder and are interested in participating in a three-week in-patient hospitalization trial. Participants must meet the following criteria:
Eligible patients will receive the following:
For more information or to see if you qualify, please contact a study coordinator at (636) 946-8032 or visit www.MidwestResearchGroup.com. Bipolar I Disorder in Teenagers (Return to Index at the Top of the Page) Your teen may be eligible to participate in a research study of an investigational medication for Bipolar Disorder if he or she is
For more information, call Mercy Health Research at 314-205-0007 ext. 120 or see our website: www.teenmental health.net. Bipolar I Disorder in Children and Teens (Return to Index at the Top of the Page) Your child or teen may be eligible to participate in a research study of an investigational medication for Bipolar I Disorder if he or she is
For more information, call Mercy Health Research at 314-205-0007 ext. 120 Treatment of Early Age Mania (TEAM) Study (Return to Index at the Top of the Page) This is the first large scale, multi-site treatment study for childhood bipolar disorder. Washington University is one of six national sites taking part in the study. The study is being funded by the National Institute of Mental Health. To participate, a child must:
More about the study….
Please contact: Samantha Blankenship, MSW or Becky James, MSW, LCSW, 314-286-2783. We are happy to answer any questions about the study or eligibility. Bipolar Disorder I Disorder (Genetics and Environment Study) (Return to Index at the Top of the Page) Washington University School of Medicine is recruiting individuals for a research study whose goal is the identification of the genetic and environmental factors associated with Bipolar Disorder. If you have been diagnosed with Bipolar I Disorder (the severe form of mania), you may be eligible to participate in our research. Participation will include:
This is NOT a treatment or drug trial study and treatment is NOT provided by this project. Research is conducted by Principal Investigator John Rice, PhD and colleagues. Research is funded by the National Institute of Mental health (NIMH) and is approved by the Human Studies Committee at Washington University School of Medicine. For more information, please call 314-286-1345 or (toll-free) 1-866-289-1378. See the study website: http://zork.wustl.edu/bipolar. Attention Deficit Hyperactivity Disorder (ADHD) (Return to Index at the Top of the Page) Is your child . . .
Mercy Health Research is conducting a research study of ADHD in children ages 6-12. If eligible, benefits include:
For more information, call: 314-205-0007 ext 120 or 1-877-883-5056. Generalized Anxiety Disorder (Return to Index at the Top of the Page) St. Charles Psychiatric Associates and Midwest Research Group are currently looking for patients who are struggling with Generalized Anxiety Disorder. If you have taken medication for Generalized Anxiety Disorder in the past and are still struggling with symptoms of excessive worry, tension, trouble sleeping, or stress, you may qualify. Criteria for study qualification:
Eligible patients will receive the following:
If you are currently suffering from symptoms of generalized anxiety disorder and are interested in potentially trying a new medication to treat your anxiety symptoms, please contact a study coordinator at (636) 946-8032 or visit www.MidwestResearchGroup.com. Insomnia (Return to Index at the Top of the Page) St. Charles Psychiatric Associates and Midwest Research Group are currently looking for patients who are struggling with symptoms of insomnia. Participants must meet the following criteria:
Eligible patients will receive the following:
For more information or to see if you qualify, please contact a study coordinator at (636) 946-8032 or visit www.MidwestResearchGroup.com.
|
